报价延迟最少15分钟:2026/01/09 07:37 EST
盘前时段
|
||||
|
-- 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
35.8
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.04/0.47
|
|
企业价值
4.02B
|
| 资产负债 |
|
每股账面净值
6.42
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
45.56M
|
|
每股收益
0.13
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
